Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

Autor: Oriol, Albert, Hájek, Roman, Spicka, Ivan, Sandhu, Irwindeep, Cohen, Yael C., Gatt, Moshe E., Mariz, José, Cavo, Michele, Berdeja, Jesús, Jin, Kexin, Bar, Merav, Das, Prianka, Motte-Mohs, Ross La, Wang, Yu, Perumal, Deepak, Costa, Luciano J.
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2024 24(10):703-714
Databáze: ScienceDirect
Externí odkaz: